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Lipoprotein (a) (Lp(a)) has been described as an important 
component of the lipid profile and a significant coronary risk 
factor when elevated. Controversy surrounds the importance 
of this lipoprotein variant, and its management is often 
challenging for clinicians. Important issues relate to the control 
and management of high Lp(a) levels, especially in patients at 
intermediate risk of cardiovascular disease. Clear guidelines 
are lacking on who needs Lp(a) measured, and when. We 
review practical points on investigating and managing Lp(a).
Background
Lp(a) was first described in 1963 as a genetic variant 
of β-lipoproteins.1 The physiological functions of Lp(a) 
remain a mystery. Most studies strongly suggest that it is 
an independent risk factor for cardiovascular disease.2 A 
meta-analysis concluded that an increased plasma level 
of Lp(a) is an independent predictor of the presence of 
coronary artery disease (CAD), particularly in patients with 
hypercholesterolaemia.3 The combination of high Lp(a) 
plasma concentrations and other cardiovascular risk factors, 
in particular low high-density lipoprotein (HDL), strongly 
increases the risk of CAD. In addition to containing significant 
amounts of cholesterol and being able to oxidise like low-
density-lipoprotein (LDL), Lp(a) can exert antifibrinolytic 
actions, stimulate the proliferation of smooth-muscle cells, 
facilitate wound healing, act as an acute-phase reactant and 
generate bioactive derivatives that are retained in the vascular 
extracellular matrix. Lp(a) has been identified as the link 
between atherosclerosis and thrombosis. Stoichiometrically the 
atherogenicity of Lp(a) is 10-fold that of LDL, though the latter 
dominates in the circulation. Lp(a) is also highly thrombogenic 
and bears structural resemblance to plasminogen, which 
explains its antifibrinolytic properties.4 
Coronary risk association
The plasma levels of oxidised phospholipids present in Lp(a) 
have been implicated in contributing to the atherogenicity of 
Lp(a),5 which is a strong independent risk factor for CAD  in 
various populations and ethnic groups.6 
Lp(a) has a significant and well-described genetic 
heterogeneity. Its risk associations with vascular disease 
demonstrate racial and ethnic variations. Higher plasma 
concentrations are seen in blacks, postmenopausal women and 
people with hypercholesterolaemia. However, the strongest 
association with high Lp(a) levels and coronary disease is 
observed in middle-aged white men. High Lp(a) levels are 
associated with a high risk of stroke in blacks and in white 
women, but not in white men.7
Not all studies associate Lp(a) with increased coronary 
risk. The Physician’s Health Study found no association 
between Lp(a) level and the risk of future ischaemic events,8 
but this observation could have been due to sampling and/or 
measurement errors. Some studies measured Lp(a) in long-
term, frozen samples with insufficiently evaluated test kits. 
Moreover, owing to the wide range of plasma Lp(a) levels from 
less than 0.001 g/l to more than 3 g/l and the highly skewed 
distribution, studies that include small numbers of cases/
controls are prone to random deviations. 
Measurement
Studies are sometimes controversial, as it is difficult to 
standardise the measurement of Lp(a) due to its heterogeneity. 
Recognition of the biological importance of apolipoprotein (a) 
(apo(a)) is also reflected by the International Standardization 
Committee, which recommends that the previous practice 
of reporting Lp(a) as a total mass be superseded by the 
measurement of Lp(a) protein either in terms of apo(a) or 
as apo(a) linked to apoB100.9 In this way the level of Lp(a) 
cholesterol can be estimated by comparing it with that of LDL, 
important information to the clinician. 
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Investigation
‘In whom should we measure Lp(a)?’ remains to be the main 
question to be answered. 
Serum levels of Lp(a) are genetically determined, with 
environmental factors having a negligible impact.10 Childhood 
levels of Lp(a) are a better predictor and marker than any 
other lipoproteins for future CAD in young adult life.11 Most 
lipidologists recommend a once-off measurement of Lp(a) 
in patients with vascular disease, especially in patients with 
premature cardiovascular disease and premature stroke, where 
other risk factors fail to explain the causation. Lp(a) is also 
useful in patients in the intermediate-risk group, according to 
the Framingham, Australian and New Zealand or Procam risk 
calculators. If Lp(a) is elevated above 0.3 g/l in these patients, 
it is very important to treat their other risk factors, especially 
LDL, aggressively.
Management
HMG-CoA (3-hydroxy-3-methyl-glutaryl-CoA) reductase 
inhibitors (statins) have no demonstrable efficacy in modifying 
Lp(a) levels. There are few means whereby plasma Lp(a) can 
be reduced, the most efficient therapeutic modalities known 
to selectively reduce plasma Lp(a) being Lp(a)-apheresis and 
nicotinic acid (Table I).
Nicotinic acid and its derivatives can reduce Lp(a) levels by 
up to 35%.2 All angiotensin-converting enzyme (ACE) inhibitors 
in monotherapy lower elevated Lp(a) plasma concentrations 
in proteinuric patients by reversing proteinuria and in turn 
reducing Lp(a) production by the liver.12 Fosinopril seems to 
be the only ACE inhibitor to reduce Lp(a) concentrations in 
non-proteinuric patients as well, probably by increasing apo(a) 
fragmentation and excretion into the urine (Kostner K et al., 
unpublished data). 
The most effective therapy for lowering Lp(a) is 
extracorporeal elimination of Lp(a) with apheresis. LDL-
apheresis and selective Lp(a)-apheresis using antibody-coupled 
columns, precipitation and complex formation at low pH, 
double filtration and direct absorption have been demonstrated 
to lower plasma Lp(a) to the same extent as LDL cholesterol 
(up to 80%).13 However, these treatments are expensive and 
accessible only to a small number of high-risk patients. 
Most lipidologists and clinicians recommend lowering LDL 
cholesterol more aggressively to levels below 1.8 mmol/l when 
the Lp(a) level is above 0.3 g/l, even though hard evidence to 
merit this practice is lacking.
Conclusion
Measurement of Lp(a) provides useful additional information 
about cardiovascular risk in patients with premature vascular 
disease and intermediate risk profiles. Aggressive LDL 
reduction and global coronary risk factor modulation are 
recommended in patients with elevated Lp(a). Coronary 
disease is an emerging major health challenge in Africa, with 
CAD projected to be the leading cause of death in Africa by 
2030.14 However, information on the role of Lp(a) as a coronary 
risk factor among developing communities, especially in Africa, 
is seriously lacking and more studies are required.
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Table I. Influence of drugs and other substances on plasma 
Lp(a) concentrations
Substance   % decrease
Omega-3 fatty acids   5 - 20
Palm oil     10 - 25
Vegetarian diet   10
Nicotinic acid and derivatives  15 - 35
Aspirin    15 - 20
L-carnitine   10 - 15
Lp(a)/LDL apheresis  60 - 80
ACE inhibitors   10 - 40
